{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hospach I"],"funding":["Baxter"],"pagination":["14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7221037"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(1)"],"pubmed_abstract":["BACKGROUND:Invasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances in extracorporeal CO2 removal (ECCO2R) technologies may facilitate more protective lung ventilation in acute respiratory distress syndrome, and enable earlier weaning and/or avoid invasive mechanical ventilation entirely in chronic obstructive pulmonary disease exacerbations. We evaluated the in vitro CO2 removal capacity of the novel PrismaLung+ ECCO2R device compared with two existing gas exchangers. METHODS:The in vitro CO2 removal capacity of the PrismaLung+ (surface area 0.8 m2, Baxter) was compared with the PrismaLung (surface area 0.35 m2, Baxter) and A.L.ONE (surface area 1.35 m2, Eurosets) devices, using a closed-loop b"],"journal":["Intensive care medicine experimental"],"pubmed_title":["In vitro characterization of PrismaLung+: a novel ECCO2R device."],"pmcid":["PMC7221037"],"funding_grant_id":["N/A"],"pubmed_authors":["Storr M","Harenski K","Laffey JG","Hospach I","Pouchoulin D","Goldstein J","Votteler S","Raible M"],"additional_accession":[]},"is_claimable":false,"name":"In vitro characterization of PrismaLung+: a novel ECCO2R device.","description":"BACKGROUND:Invasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances in extracorporeal CO2 removal (ECCO2R) technologies may facilitate more protective lung ventilation in acute respiratory distress syndrome, and enable earlier weaning and/or avoid invasive mechanical ventilation entirely in chronic obstructive pulmonary disease exacerbations. We evaluated the in vitro CO2 removal capacity of the novel PrismaLung+ ECCO2R device compared with two existing gas exchangers. METHODS:The in vitro CO2 removal capacity of the PrismaLung+ (surface area 0.8 m2, Baxter) was compared with the PrismaLung (surface area 0.35 m2, Baxter) and A.L.ONE (surface area 1.35 m2, Eurosets) devices, using a closed-loop b","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-06-01T03:23:01.083Z","creation":"2020-05-22T20:13:29Z"},"accession":"S-EPMC7221037","cross_references":{"pubmed":["32405714"],"doi":["10.1186/s40635-020-00301-7"]}}